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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
is one of the European Union’s decentralised agencies. Established in 1993
and based in Lisbon, it is the central source of comprehensive information
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable and
comparable information on drugs and drug addiction. In doing so, it
provides its audiences with an evidence-based picture of the drug
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide
range of audiences including policy-makers and their advisors;
professionals and researchers working in the drugs field; and, more
broadly, the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug
phenomenon in the EU and is an essential reference book for those seeking
the latest findings on drugs in Europe.
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Overview
The use of pharmacological agents is one of the most
common approaches in the treatment of opiate dependence.
Early in the 20th century (Ministry of Health, 1926),
authorities in some European countries realised the value 
of prescribing an opioid drug either as an aid to withdrawal
or as a substitution medicine for patients who were addicted
to heroin, morphine or opium. Today the most commonly
used opioid substitution drug in Europe and the developed
world is methadone, which was first introduced in the USA.
A number of factors make this drug a popular therapeutic
agent: it has a relatively long half-life (22 to 36 hours);
it can be administered orally; and there is a strong scientific
evidence base for its therapeutic efficacy. However, despite
its popularity, the use of methadone continues to cause some
concern, for example regarding the potential for it to be
diverted to the illicit market, the level of withdrawal distress
associated with cessation of the drug and the potential for
overdose when used outside therapeutic settings. 
These concerns have been partly responsible for the
development of interest in other withdrawal agents that can
provide the same benefits as methadone but which may 
be more appropriate to some clinical settings or better 
suited to the needs of some client groups.
One drug that appears to deliver some of these benefits 
is buprenorphine. This mixed agonist/antagonist has
historically been used for the short-term treatment 
of moderate to severe pain. Since the mid-1990s,
buprenorphine has increasingly become available in Europe
as an alternative to methadone for the treatment of opiate
dependence. In this special issue, the reasons why clinicians
are attracted to this drug, as well as the costs and benefits 
of buprenorphine in comparison with other treatment options,
are explored in detail, and, for the first time, the increasing
popularity of buprenorphine for the treatment of opiate
dependence in many European countries is documented.
Introduction: legislation and
pharmacological action
Buprenorphine is classified under Schedule III of the 
United Nations Convention of Psychotropic Substances of
1971, requiring all countries to place it under control. 
By comparison, methadone is classified under Schedule I
of the 1961 Convention, which places more restrictive
measures on its control, distribution and use.
Buprenorphine is a derivate of the morphine alkaloid
thebaine and, in contrast to methadone, which is a full opiate
agonist, it is a mixed agonist/antagonist. This means that
buprenorphine only partially activates the opiate receptors
within the nervous system, producing a milder effect with
both less euphoria and less sedation (Ridge et al., 2004).
Buprenorphine is often described as a partial agonist
(receptor stimulator)/antagonist (prevents receptor
stimulation) (Jones, 2004) (Figure 1) because it has
important actions on two types of opiate receptors in the
brain. Many of the most common opioid effects, such as
euphoria, respiratory effects and reduced pain sensation,
are caused by stimulation of the mu receptor.
Buprenorphine produces these effects because it stimulates
the mu receptor, albeit at lower intensity than other opiates
such as heroin or methadone. Additionally, however, as
buprenorphine binds more strongly to the receptor than
these drugs, it can displace them. As a result, an individual
who takes buprenorphine while dependent on another
opioid risks the development of withdrawal symptoms due
to a reduction in stimulation of the receptor. In addition,
disassociation of buprenorphine from the receptor is slow,
accounting for the drug’s long duration of action, one of
the factors that makes it a versatile treatment option.
Buprenorphine is also an antagonist of another receptor
associated with opioid effects. The kappa opioid receptor
is associated with some of the negative effects experienced
in withdrawal, particularly depression. As buprenorphine
inhibits stimulation of this receptor it may produce feelings
of well-being.
Studies have shown that buprenorphine can be effective
for the treatment of opiate dependence. In addition, it has
been argued that the pharmacology of buprenorphine
provides a number of benefits: its mixed opioid
stimulating/blocking action makes it a relatively safer
option in terms of the risk of overdose; its properties make
it a less attractive drug to the illicit user and it may
therefore be less likely than other opiates to be diverted
onto the illicit market; cessation of the drug is associated
with milder levels of withdrawal distress; and the long
duration of its action permits more flexible dispensing
options. Taken together, these factors may make
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available under the brand name Subutex. These tablets are
specifically intended for the treatment of problem drug use
in clients who are being maintained in medically assisted
treatment; in the case of clients undergoing withdrawal
treatment, they are administered in a gradually reducing
dose. Low-dose tablets are sometimes used for the treatment
of opiate dependence, in which case multiple tablets are
prescribed in order to achieve the desired dose.
In some countries buprenorphine is also available in
another formulation, under the brand name Suboxone; in
this case, buprenorphine is combined in a 4:1 ratio with
the opiate antagonist naloxone. Suboxone was developed
to reduce the abuse and diversion potential of
buprenorphine by making its injection undesirable 
(Chiang and Hawks, 2003). Naloxone, in contrast to
buprenorphine, has little effect when taken sublingually.
However, when injected, the antagonist properties of
naloxone can precipitate a withdrawal syndrome in
anyone who is opiate dependent. Not surprisingly, this is
thought to make the drug less attractive to those who inject
buprenorphine a versatile therapeutic agent and provide
clinicians with an important additional prescribing option,
although questions about which client groups are best
treated with buprenorphine and which clients may be
better suited to a different treatment option remain
unanswered. In particular, it has been suggested that the
pharmacological action of buprenorphine may make it less
attractive to some client groups and that other benefits
have to be weighed carefully against the cost of the drug.
Common formulations
Buprenorphine is available as tablets to be taken
sublingually (allowed to dissolve under the tongue), or as
ampoules for intramuscular or subcutaneous injection. Low-
dose tablets, containing 0.2–0.4 mg of the drug, are sold
under the brand name Temgesic and are normally used for
analgesic purposes, for relief from moderate to severe pain.
The most common formulation of buprenorphine used for
the treatment of opiate dependence is high-dose tablets
containing 8–16 mg buprenorphine hydrochloride and
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Figure 1: Effects of buprenorphine, heroin and naloxone on the mu opioid receptor
NB: The mu receptor is one of the primary sites for the reward effects of opiate drugs in the brain. The opiate binds to the affinity zone of the receptor and stimulates
the activity zone, thereby producing an effect. In the diagram, heroin, buprenorphine and naloxone are represented by blue polygons, and the receptors by yellow
polygons. The stimulatory effect of each chemical is related to how it interacts with the affinity zone (represented here as filling a proportion of the affinity zone).
Heroin, classified as a full receptor agonist (stimulator), almost fills the activity zone while buprenorphine, a partial receptor agonist, fills a smaller proportion of
it and naloxone does not stimulate the receptor at all. The substances also differ in how strongly they bind to the receptors. A substance that binds more strongly
to the receptor can displace a substance that binds less strongly. Thus, buprenorphine can displace both naloxone and heroin, and naloxone can displace heroin.
Source: Adapted from Jones, H. E. (2004), ‘Practical considerations for the clinical use of buprenorphine’, Science and Practice Perspectives 2, No 2, pp. 4–20.
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drugs and thus lower the risk of diversion onto the illicit
drug market. However, many problem opiate users in
Europe do not inject drugs, and studies of illicit drug users
have reported the use of non-prescribed Temgesic and
Subutex tablets.
Treatment efficacy
Although the research literature is still developing, and
questions remain regarding which patients are best suited to
treatment with buprenorphine compared with other treatment
options, a number of studies have suggested that
buprenorphine can be effective in the treatment of opiate
dependence. It should be remembered that prescribing for
substitution or withdrawal management is likely to be only
one part of a therapeutic intervention, and overall success
rates are likely to be influenced by the overall package of
care provided. Nonetheless, studies have suggested that
buprenorphine can have a positive effect on a number of
outcome measures, including reduced drug use, increased
treatment retention rates and improved health status (Strain et
al., 1994). Clinical approval of the drug also appears high.
Studies have also shown that client acceptance of the drug is
good, although questions remain about its attractiveness to
all client groups and whether this has an effect on treatment
uptake or retention (Schottenfeld et al., 1997). The question
of which client groups are best suited to buprenorphine
therefore remains an important one for further research.
Contraindications to buprenorphine treatment include a
number of medical conditions (Jones, 2004) such as
respiratory, kidney or gall bladder problems, mental
disorders, head injury, adrenal or thyroid dysfunction,
enlarged prostate and urination problems. Caution is also
required in patients with hepatitis or impaired liver
function as the impact of the drug on the liver requires
further study. The suitability of buprenorphine for use by
pregnant women remains open to debate. One study
reported that the neonatal abstinence syndrome was less
intense with buprenorphine than with methadone (Johnson
et al., 2003), but again this is an area in which further
studies are required.
Table 1 describes the pharmacological properties of
buprenorphine and their clinical implications (Lintzeris 
et al., 2001).
The suitability of buprenorphine for use by pregnant
women remains open to debate and the scientific evidence
for the effects of buprenorphine use during pregnancy
remains incomplete. In the USA, clinicians are currently
advised to switch pregnant women from buprenorphine to
a methadone prescription, partly because it seems clear
that the therapeutic benefits of methadone are likely to
outweigh any potential risks to the unborn child and this
evidence base for buprenorphine is less complete. 
There are some concerns that, compared with methadone,
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Table 1: Summary of the pharmacological and clinical properties of buprenorphine
Property Clinical implication
Produces opioid effects Reduces cravings for heroin and enhances treatment retention
Less sedating than full agonists (heroin, morphine, methadone)
Prevents or alleviates heroin Can be used for maintenance or withdrawal treatment
withdrawal symptoms
Diminishes the effects Diminishes psychological reinforcement of continued heroin use
of additional opioid use May complicate attempts at analgesia with other opioid (e.g. morphine)
(e.g. heroin)
Long duration of action Allows for once-a-day to three-times-a-week dosing schedules
Ceiling on dose–response Higher doses (e.g. >16 mg) may not increase the opioid agonist effects, while prolonging the duration of action
effect Safer in overdose, as high doses in isolation rarely result in fatal respiratory depression
Sublingual preparation Safer in accidental overdose (e.g. children) as poorly absorbed orally
More time involved in supervised dispensing
No severe withdrawal Treatment with naltrexone can be commenced within days of buprenorphine
precipitated by opioid May complicate management of heroin overdose requiring high naloxone doses
antagonists
Side-effect profile similar Generally well tolerated, with most effects transient
to that of the opioids
Source: Lintzeris et al. (2001).
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outcomes in terms of retention rates and reduction in drug
use (Strain et al., 1994; Schottenfeld et al., 1997). 
Some specific advantages of buprenorphine in the
treatment of opiate dependence have also been reported.
Compared with methadone, buprenorphine causes less
sedation and users are more clear-headed; administration
is also more flexible, which is useful in primary care
settings (Fiellin et al., 2002) or at home, and the drug is
well tolerated at high doses and has a safer profile. On the
other hand, it has been suggested that methadone may be
a more attractive drug (see, for example, Conférence de
Consensus, 2004) to some client groups, especially those
with long-term problems or a poor record of treatment
compliance. This remains an important question for further
study and should be seen as part of a broader debate on
prescribing options for those with problems related to
opioid dependence.
It remains unclear whether buprenorphine is superior to
methadone regarding retention of clients in treatment and
reduction of clients’ additional consumption of illicit drugs.
Some studies concluded that methadone is 
more effective than buprenorphine in retaining clients 
in treatment (Kosten et al., 1993; Ling et al., 1996), 
others have found no significant differences in retention
rates (Strain et al., 1994; Schottenfeld et al., 1997).
Similarly, claims that buprenorphine-maintained clients
consumed significantly less additional opioids and cocaine
than methadone-maintained clients (Giacomuzzi et al.,
2003) must be weighed against research that found no 
significant differences between clients maintained on these
two substances (Strain et al., 1994).
As buprenorphine is less hepatotoxic than methadone and
is less likely than the latter to cause cardiac arrhythmias,
renal disease and aggravate affective and psychotic
disorders, buprenorphine may be particularly suitable for
the following groups of patients:
• those with a short addiction history and good motivation
(Kastelic and Scott, 1998);
• those with heart or renal disease;
• those with psychotic and affective disorders.
Historical development
American experts first suggested in 1980 that there was 
a scientific basis for the use of buprenorphine in the
treatment of opiate dependence (Jasinski et al., 1978;
Mello and Mendelson, 1980). Research work followed,
and the drug was approved by the US Food and Drug
Administration (FDA) as a narcotic for use in treating opioid
dependence in men and non-pregnant women in 2002.
buprenorphine may be more likely to induce abstinence
syndrome in the neonate and it is thought to cause higher
neonatal toxicity during breast feeding (Lintzeris et al.,
2001). However, some studies have shown buprenorphine
to be both effective and well tolerated by mother and
foetus, and one study reported that the neonatal
abstinence syndrome was less intense with buprenorphine
than with methadone (Johnson et al., 2003). Clearly,
further research in this area is required. 
Buprenorphine costs considerably more than methadone
but some economic analysis has suggested that the relative
costs of methadone and buprenorphine treatment can be
similar. This rests on the assumption that buprenorphine
may allow the possibility for less frequent administration. 
As the total cost of the intervention will consist of both the
drug cost and the cost of clinical resources necessary to
administer the drug (staff time, use of facilities, etc.) this may
generate savings in terms of the input of clinical staff and
other resources. For example, Ridge et al. (2004) estimated
the cost of buprenorphine treatment to be around 1.3 times
higher than that of methadone treatment. However, the
extent to which available studies are relevant to the
European situation as a whole is unclear. Clinical costs vary
considerably between countries and prescribing costs may
be difficult to separate out in practice from other elements
of the care package provided. Methadone prescribing
practices also vary considerably between countries and
may also differ according to patient characteristics. The
extent to which buprenorphine costs are similar to or
exceed methadone costs are therefore likely to vary
according to both local factors as well as the extent to
which different prescribing regimes are implemented for
each drug. However, both methadone and buprenorphine
are generally assessed as being cheaper than other
pharmacological substitution options, such as lofexidine.
Although there appears to be a growing consensus that the
overall attractiveness of buprenorphine as a drug on the
illicit European market is likely to be limited, and therefore
diversion is potentially a smaller problem than with other
opiates, this contention remains to a large extent
speculative because of the limited evidence currently
available. Buprenorphine, like all opiates, has the
potential for misuse. Sources of harm include injection and
combined use with other substances, in particular
benzodiazepines and alcohol. As it is a relatively new
substance in Europe, in many countries few data are yet
available to inform a discussion on buprenorphine misuse
and further research is therefore a priority.
Comparison with methadone
Some studies have compared the effectiveness of
buprenorphine and methadone and found similar
38
(1) Belgium, Denmark, France, Germany, Italy, Austria and the UK (EMCDDA, 2000).
(2) http://www.anit.asso.fr/docs/subutex_1.php.
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Buprenorphine had been used as an analgesic in Australia
and Europe since the mid-1980s, but its role in the
treatment of dependence came somewhat later. Typically in
European countries, formal recognition of the drug as an
approved approach in the treatment of opioid dependence
followed a successful small experimental or ad hoc trial. For
example, France, in the early 1990s, was one of the first
European countries to use buprenorphine to any significant
extent for the treatment of opiate dependence, but it was
not until 1996 that a formal legal framework for its use was
adopted. Similarly in Belgium, limited use of buprenorphine
can be traced back as far as 1984, but the legal basis for
its use was only put in place in 2004. More recently, the
period between experimental and formal use appears to be
decreasing as the evidence base for the effectiveness of the
drug has grown; for example, Finland reports some limited
use from around 1997 and a legal basis being put in place
in place in 1999.
Substitution treatment in general increased in popularity in
Europe during the 1990s, but for the most part the drug of
choice for clinicians was methadone. Although high-
dosage buprenorphine treatment was available in eight
Member States by the year 2000, availability continued to
be limited in comparison with methadone treatment (1).
By 2004, all of the old 15 Member States, except Ireland,
reported some use of high-dosage buprenorphine
treatment (HDBT) for opioid dependence — in Ireland,
buprenorphine use is restricted to withdrawal treatment.
Among the new Member States, the Czech Republic,
Estonia and Lithuania reported the launch of HDBT in
2004, and in Slovenia it was implemented in 2005. In the
Czech Republic, there are now more clients in HDBT than
in methadone treatment.
In addition to scientific evidence for the effectiveness of
buprenorphine in the treatment of opiate dependence,
other contextual factors contributed to its introduction in
the European countries: insufficient availability of
methadone treatment to meet the increased demand;
irregular coverage of substitution treatment at national
level in several countries; the spread of AIDS; and, finally,
political debates on alternatives to methadone (2).
Treatment provision of buprenorphine
Figure 2 shows which countries use high-dosage
buprenorphine treatment (HDBT), and when it was
introduced, but it does not reveal anything about the extent
or effectiveness of HDBT (for an overview of clients in
HDBT see the section on opiate treatment in Annual
report 2005: the state of the drugs problem in Europe,
Chapter 6).
The majority of Member States report the use of HDBT,
mostly the old Member States. Thirteen of the old Member
States (all but Ireland and Spain) report modest to
extensive use of HDBT. Ireland uses buprenorphine only in
withdrawal treatment, and Spain reports extremely low
use, with a mere 36 clients receiving HDBT compared with
88 678 clients in methadone treatment, constituting a mere
0.04 % of the total treatment population.
Four of the 10 new Member States (the Czech Republic,
Estonia, Lithuania and Slovenia) report use, or planned
use, of HDBT but to a very limited extent (13 clients in
Estonia in 2003, very modest use in Lithuania and no
current clients in Slovenia). Only the Czech Republic
reports relatively extensive use, with an estimated 
1 400 buprenorphine clients being treated either in
specialised units or at general practitioners.
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Figure 2: High-dosage buprenorphine treatment in Europe 
(EU Member States, Bulgaria, Romania and Norway)
Source: Standard table on drug-related treatment availability.
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13 000 clients being treated with HDBT in specialised 
units and 70 000 at general practitioners, a total of
83 000 HDBT clients. The most recent prevalence estimate
of problem drug use in France is around 180 000, giving a
coverage rate for HDBT of about 46 % (there are also clients
in methadone treatment). The same calculation for the Czech
Republic gives an HDBT coverage rate of between 10.8 and
15.6 % (1 400 clients in HDBT divided by somewhere
between 9 000 and 13 000 opiate problem drug users).
Out of the second group of countries, Norway aims to
have buprenorphine on ‘equal terms’ with methadone, but
this has not yet been achieved.
Looking at an aggregated European level, the following
picture of HDBT clients as a proportion of MAT emerges.
Overall, around 20 % of clients in MAT in the EU today
receive buprenorphine (Figure 4). However, around 77 %
(83 000 of 107 156) of these clients are in France. 
After subtracting the figures for France, the number 
of clients in HDBT constitutes a mere 5 % of the total 
(24 156 of 441 046). Thus, although buprenorphine
treatment is now available in many EU countries, in the
vast majority of Member States the actual number of HDBT
clients is still very small. The expansion of HDBT is in fact
very ‘superficial’ and its geographical distribution very
uneven. Even in France, the geographic distribution of
HDBT is rather unequal (Feroni et al., 2004).Neither of the candidate countries, Romania and Bulgaria,
reports the use of buprenorphine, although it has been
allowed in Romania since 2000.
Clients and coverage of high-dosage buprenorphine
treatment (HDBT)
Analysis of the proportion of clients being treated with
buprenorphine out of the total number of clients in medically
assisted treatment (MAT) reveals two distinct groups of
countries (Figure 3). In the first group (which comprises the
Czech Republic, France and Sweden), clients receiving
HDBT account for more than 60 % of the national
aggregated number of clients in MAT. In France, in
particular, buprenorphine treatment spread quite rapidly,
because of some restrictions in methadone access (strict
requirement for access, few places, reluctance of doctors in
providing methadone) and because buprenorphine was
judged as a safer and effective alternative to methadone.
The second category comprises countries where HDBT
accounts for less than 25 % of the total MAT (Denmark, Italy,
Luxembourg, Norway). In both cases, it must be kept in
mind that these figures are only relative and reveal nothing
about the overall national provision of MAT or HDBT.
Taking the countries in the first group (>60 % in HDBT), 
the detailed figures are as follows. France reports 
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Figure 3: Buprenorphine clients as a percentage 
of all medically assisted treatment clients
Source: Standard table on drug treatment.
0
10
20
30
40
50
60
70
80
90
C
ze
ch
 R
ep
ub
lic
 
D
en
m
ar
k
Fr
an
ce
Ita
ly
Lu
xe
m
bo
ur
g
Po
rtu
ga
l
Sw
ed
en
N
or
w
ay
%
Figure 4: Breakdown of medically assisted treatment (MAT)
including high-dosage buprenorphine treatment in Europe 
(EU Member States, Bulgaria, Romania and Norway)
Source: Standard table on drug treatment.
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Prescription practices, admission criteria 
and guidelines for treatment
Although prescription practices are complex and can vary
considerably even within a Member State, some common
features can be identified. HDBT will typically be provided
through two main channels: specialised units (which can
be independent units or wards linked to a mental health
centre or hospital) and general practitioners. Very often
complete and fully reliable quantitative data regarding the
provision of HDBT are not available, but reports from
Member States suggest the following general trends.
In some countries (Denmark, Estonia, Greece, Spain, 
Italy, Finland, Sweden, Norway) HDBT is provided
predominantly, if not exclusively, by specialised units,
whereas in other countries (the Czech Republic, Germany,
France, Luxembourg) HDBT is provided mainly by general
practitioners. In a third group of countries (Belgium,
Lithuania, Austria) it is not possible to establish the main
provision channel. The role of general practitioners varies
greatly among Member States; in some countries
(Denmark, Greece, Sweden) general practitioners have 
no involvement while in others (Czech Republic, France)
they are the main provider.
Admission criteria and/or rules related to the prescription
and delivery of HDBT also vary among Member States. 
For example, the minimum age for treatment is 16 years 
in the UK, 18 years in Portugal, 20 years in Greece and
Sweden, and 25 years in Norway.
Other admission criteria for the provision of buprenorphine
include the following: buprenorphine should not be given
to heroin injectors (Belgium), clients should be more
motivated than others to quit drugs (Italy), the user should
be dependent on opiates (France), users must meet the
criteria of WHO’s ICD-10 (Denmark). As discussed earlier,
no clear consensus exists on the prescription of
buprenorphine during pregnancy. The clinical practice in
Belgium, the Netherlands and Portugal is to avoid
prescribing buprenorphine to pregnant women while in
contrast, in Austria and Norway, it is recommended.
Misuse of buprenorphine
Buprenorphine, like all opiates, has the potential to be
misused and, despite its relatively safer profile (Greenstein
et al., 1997), cases of buprenorphine misuse have been
reported. The combination of buprenorphine and other
sedatives (such as alcohol, benzodiazepines, barbiturates,
tricyclic antidepressants or major tranquillisers) can cause
serious interactions that can result in respiratory
depression and overdose. 
Buprenorphine is readily injected if the tablets are crushed
and dissolved in water, with the related risks of viral
contamination; in addition, since it is not completely
soluble in water (Guichard et al., 2003), injection is
associated with specific risks such as skin infections,
abscesses, oedema and vascular infections. Finally,
injection of buprenorphine that has already been in the
mouth can result in systemic fungal or bacterial infections
(Lintzeris et al., 2001). 
Prevalence of buprenorphine misuse
Data on buprenorphine misuse are scarce and not
harmonised at European level. In 2004, the EU Member
States provided specific information on buprenorphine
misuse (3): out of 17 countries where buprenorphine
treatment is available, 12 reported some misuse of
buprenorphine, albeit often extremely rare.
The two countries where the problem is most visible are
Finland and France. In Finland, 28 % of persons entering
drug treatment and 90 % of opiate users reported that they
had buprenorphine as a primary drug leading to
treatment; in France the corresponding figures were 5.8 %
and 8.3 %.
Elsewhere, the number of buprenorphine misusers is much
lower; in the Czech Republic, Denmark, Germany and
Sweden, buprenorphine misuse is referred to only in
informal sources; in the other countries, misuse is reported
to be extremely rare (close to zero).
Very little information is available on trends in
buprenorphine misuse in European countries, although
there are some indications of a recent increase. The
prevalence of buprenorphine misuse is highest in Finland,
which has reported a steady increase of drug clients
among persons entering drug treatment over the last 
four years (+170 %).
Studies carried out among specific populations have
revealed that the proportion of buprenorphine misusers is
higher among patients of low-threshold services (up to 
41 % in France), among substitution treatment clients
(Norway) and among disadvantaged and marginalised
young people. Misuse of high-dose buprenorphine is also
reported to be quite common among homeless people
living in urban regions, partly because the combination of
greater flexibility of administration and easy access 
to the substance can play a role in attracting users who 
41
(3) The TDI European protocol on people demanding treatment for their drug use provides information on clients using opiates as substitution treatment or 
as a primary and secondary drug of abuse; buprenorphine is included in the ‘other opiates’ category and only occasionally is the type of opiate
specified. Specifications and qualitative information on buprenorphine were requested from the EU Member States in the 2004 Reitox national reports.
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Data on route of administration of buprenorphine misuse
are very limited; in Finland and France, where the problem
is more common, most buprenorphine misusers inject the
substance (90 % of Finnish drug clients). In France, it is
reported that injection is more common among less socially
integrated people. Nevertheless, indications of a decrease
in buprenorphine injection in recent years are reported.
French studies reveal that buprenorphine injection
increases the risk of respiratory depression, overdose, skin
and vascular infections and is more likely than some other
drugs to cause abscess, thrombosis and haematomas
(Table 3) (Escots and Fahet, 2004; OFDT, 2004).
Specific risk factors for buprenorphine injection are
reported to be polydrug use, precarious economic
conditions and insufficient doses of buprenorphine for
people in treatment setting (Vidal-Trecan et al., 2003).
Deaths
Deaths due to buprenorphine misuse are very rare, 
and it is thought that the risk of overdose is lower with
buprenorphine than with other opioids because of its
agonist/antagonist pharmacological characteristics 
(i.e. beyond a certain dose a further increase does not
result in any further increase in effect) and because its usual
administration is sublingual (see also the introduction).
Despite this, some deaths have been reported in the
scientific literature and by some European countries.
However, data are very limited and in most cases
buprenorphine is detected in the blood together with other
substances, often benzodiazepines or alcohol. It is thought
do not want a regular setting for care and partly because
drug users who have received buprenorphine treatment
sometimes switch to misusing the drug (Blanchon et al.,
2003).
According to the available information, buprenorphine
misusers seem to differ from other opiate users in several
respects: they are reported to be younger, enter treatment
earlier, start injecting sooner, and inject more often (Reitox
national reports, 2004).
Two distinct groups of buprenorphine misusers are
reported:
• those who self-medicate with the aim of stopping using
other opiates; reasons for this type of misuse might be
insufficient availability of substitution treatment or the
desire to remain anonymous and keep away from the
public health system (OFDT, 2004);
• drug addicts who use buprenorphine as drug of abuse,
either as replacement for heroin (if heroin is not
available or as a breakdown product) or as a primary
drug of choice; reasons for this type of misuse may
include the specific desirable effects of the substance, its
accessibility and the opportunity to evade urine analysis
in countries where it is not possible to measure
buprenorphine in urine samples (e.g. Denmark).
Younger people are reported to use the drug more often as
the primary drug of choice, whereas older users more
often use buprenorphine as ‘self-medication’ (Table 2).
Patterns and consequences of buprenorphine misuse
When buprenorphine is misused, it is often injected in
combination with other substances, particularly
benzodiazepines and other sedatives, alcohol and, to a
lesser extent, cocaine and other stimulants. 
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Table 2: Frequency of reasons for use of HDB 
in the past month, in 2003, among participants
in the ‘2003 low-threshold’ survey by age group
in France
Sources: TREND/OFDT (Escots and Fahet, 2004).
Reason Age (years)
for use 15–24 (%) 25–34 (%) 35 and over (%) All (%)
As treatment 47 50 66 54
To ‘get high’ 20 10 13 13
Both 33 40 21 34
Total 100 (n = 80) 100 (n = 209) 100 (n = 100) 100 (n = 389)
Table 3: Frequencies and odds ratios (ORs) of risks
associated with the injection of Subutex or other
substances during the past month in France
Subutex Injectors of other OR and 95 % 
injectors (%) substances (%) confidence interval 
Abscess 31 19 1.9 [1.2–3.1]
Injection
difficulties 68 55 1.7 [1.1–2.6]
Blocked vein, 42 30 1.7 [1.1–2.5]
thrombosis,
phlebitis
Swelling  44 26 2.3 [1.5 –3.5]
of hands 
or forearms
Febrile episodes 27 22 1.4 [0.9–2.1]
Haematoma 44 36 1.4 [0.9–2.1]
Sources: TREND/OFDT (Escots and Fahet, 2004).
(4) The 112 (119) cases in France occurred between 1996 and 2001 (there were only eight deaths in 2003), and the two cases in Luxembourg between
1992 and 2003, whereas the 40 cases in Finland occurred in a single year. The relative risk is very different.
Selected issue 3: Buprenorphine — treatment, misuse and prescription practices
that the risk of overdose is highest with intravenous
injection and concomitant use of alcohol and sedatives.
Five European Member States in 2003 reported post-
mortem findings of buprenorphine in the blood. Eight
reported cases in France, and 44 in Finland, were linked
to Subutex. The difference between the two countries is
striking given that in France between 72 000 and 
85 000 people were receiving buprenorphine substitution
treatment, whereas in Finland 460 patients were treated in
2004 with buprenorphine. In Finland, buprenorphine is
frequently used as a substance of abuse, and in 2003 
90 % of users entering treatment were injecting it. But in
France too about one third of those using buprenorphine
outside a protocol injected the substance. Finally, two
deaths associated with buprenorphine were reported in
Luxembourg and two in Sweden (4).
Comparing data on the number of deaths related to
methadone misuse and the number of deaths related to
buprenorphine misuse, buprenorphine appears to be
associated with a lower risk than methadone. For instance,
in France in 2003, eight deaths related to buprenorphine
were reported, out of 72 000 to 85 000 people receiving
buprenorphine substitution treatment; by comparison, there
were also eight deaths related to methadone, out of a total
of 11 000 to 17 000 treatment clients (French national
report). However, data limitations should be taken into
account (Pirnay et al., 2004).
Very little information is available on the measures
adopted by European countries to reduce harm from
buprenorphine misuse. Generic measures targeted at all
drug users, but especially those who use opiates, including
buprenorphine, include counselling, needle exchange and
the use of filters.
The use of naloxone combined with buprenorphine
(Suboxone) is mentioned as a specific measure to prevent
overdoses, decreasing the likelihood of abuse 
(CESAR Fax, 2003).
Illicit market
Information on the availability of buprenorphine on the
black market is also very limited. Diversion of
buprenorphine to the illegal market is reported in Austria
(where it is very rare), the Czech Republic, Estonia, France
and Finland. In the last four countries, there seems to be an
inverse relation between the legal availability of the drug,
which depends on the nature of national regulations, and
diversion to the illegal market.
A tightening of national regulations in the Czech Republic
and national importing regulations of pharmaceuticals in
Finland resulted in a decrease in the availability of
buprenorphine on the legal market; as demand for
buprenorphine remained stable or even increased (e.g.
Finland), this appears to have contributed to an increase in
availability of the substance on the black market.
In contrast, in Estonia and France, ease of access to
buprenorphine through doctors’ prescriptions or
pharmacies has contributed to a generally increased
availability on the legal and illegal market. In France,
clients can obtain several prescriptions by going from one
doctor to another (so-called ‘doctor shopping’), while
Estonian users supply the Finnish illegal market. In Estonia,
specific measures have now been adopted, and political
agreements with Finland negotiated, to prevent the
diversion of buprenorphine.
In addition, in Finland, a decrease in the availability of
heroin, resulting from a reduction in heroin production in
Afghanistan, is reported to be a crucial factor in the
increase in buprenorphine availability in the illegal market
(Nordic studies on alcohol and drugs, 2004).
Another element which has contributed to the increase in
buprenorphine demand and availability is the low cost of
the drug in the illegal market. In Finland, an 8 mg tablet of
buprenorphine costs EUR 30–35, whereas the price of
heroin is around EUR 60–350 per gram; in France, the
price of an 8 mg buprenorphine tablet varies from 
EUR 1 to 4. Indications of a current decrease in the price
of buprenorphine on the illegal market are also reported.
Conclusions
Buprenorphine appears to represent a valuable additional
prescribing option for clinicians treating opiate
dependence. The pharmacology of this drug may also help
in making medically assisted treatment more widely
available and more easily accessible, if it results in more
flexibility in prescribing options. In particular, this could be
the case if buprenorphine were to be considered as 
a particularly suitable treatment option for prescribing 
by non-specialist general practitioners. Largely, any
increased flexibility in prescribing options will be
dependent on existing national guidelines and practice 
on methadone distribution. And to some extent, those
countries where buprenorphine provision is currently 
most common, historically have tended to have a fairly
restrictive approach to methadone provision. This may 
be changing as several countries appear to be developing
a flexible approach in this area, where buprenorphine 
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treatment option. Compared with methadone,
buprenorphine has advantages and disadvantages, 
but it can be viewed as an alternative and relatively safe
drug that has proved efficient in both withdrawal and
maintenance treatment. Although there are reasons why
buprenorphine may be not a particularly attractive drug 
to illicit opiate users, a risk of diversion to the illicit market
still exists and therefore measures to diminish diversion
and misuse are necessary. It may be that the introduction
of new formulations of the drug may reduce this risk further
but, again, questions of cost and benefits will need to be
carefully elaborated. Finally, information and data on use
of buprenorphine in the treatment of opiate dependence
and buprenorphine misuse in the EU Member States are
still insufficient, and more research and investigation are
needed although the current evidence base does suggest
that the drug may represent a valuable addition to the
clinical arsenal for treating opiate dependence. 
is available alongside methadone as a possible treatment
option. In this respect, buprenorphine can be seen as a
valuable additional element to the options available to
clinicians and may provide some useful benefits in treating
some groups of patients or prescribing in some settings.
On the other hand, drawing conclusions about the relative
costs and benefits of this drug in comparison to other
treatment options is not a simple question. Certainly, it
would be a concern if the use of buprenorphine meant that
overall access to treatment became more limited due 
to cost constraints. Additionally, there are still questions
about which groups of clients are likely to benefit most
from which prescribing option and this remains an
important area for future research.
That said, with some notable exceptions, most Member
States report that the use of buprenorphine treatment
appears to be low to modest and it would appear that
there is considerable scope to improve availability to this
44
References
Blanchon, T., Boissonnas, A., Varescon, I. and Vidal-Trecan, G. (2003),
‘Homelessness and high-dosage buprenorphine misuse’, 
Substance Use and Misuse 38, pp. 429–42.
Cesar Fax (2003), ‘Buprenorphine now available for treating heroin
dependence in US’, CESAR Fax 12, Issue 13.
Chiang, N. C. and Hawks, R. L. (2003), ‘Pharmacokinetics of the
combination tablet of buprenorphine and naloxone’, Drug and Alcohol
Dependence 70, pp. 39–47.
Conférence de Consensus (2004), ‘Stratégies thérapeutiques pour les
personnes dépendantes des opiacés: place des traitement de substitution’.
23–24 June 2004, Lyon. Issued by FFA and ANAES.
EMCDDA (2000), Annual report 2000: the state of the drug problem 
in the European Union and Norway, European Monitoring Centre 
for Drugs and Drug Addiction, Lisbon.
Escot, S. and Fahet, G. (2004), Usages non substitufs de la buprénorphine
haut dosage, investigation menée en France, en 2002–2003, Trend, Août,
Paris.
Feroni, I., Paraponaris, A., Aubisson, S., et al. (2004), 
‘Prescription de buprenorphine haut dosage par des médecins généralistes’,
Epidemiol Santé Publique 52, pp. 511–22.
Fiellin, A. D., Pantalon, M. V., Pakes, P. J., et al. (2002), 
‘Treatment of heroin dependence with buprenorphine in primary care’,
American Journal of Drug and Alcohol Abuse 28, pp. 231–41.
Giacomuzzi, S., Riemer, Y., Ertl, M., Kemmler, G., Rossler, H., Hinterhuber,
H. and Kurz, M. (2003), ‘Buprenorphine versus methadone maintenance
treatment in an ambulant setting: a health-related quality of life assessment’,
Addiction 98 (5), pp. 693–702.
Greenstein, R. A., Fudala, P. J. and O’Brien, C. P. (1997), ‘Alternative
pharmacotherapies for opiate addiction’, in Lowinson, J. H., Ruiz, 
P., Millman, R. B. and Langrod, J. G. (editors), Substance abuse — 
a comprehensive textbook, Williams & Wilkins, Baltimore.
Guichard, A., Lert, F., Calderon, C., et al. (2003), ‘Illicit drug use 
and injection practices among drug users on methadone 
and buprenorphine maintenance treatment in France’, 
Addiction 98, pp. 1585–97.
Jasinski, D. R., Pevnick, J. S. and Griffith, J. D. (1978), 
‘Human pharmacology and abuse potential of the analgesic
buprenorphine’, Archives of General Psychiatry 35, pp. 501–16.
Johnson, R. E., Jones, H. E., and Fischer, G. (2003), 
‘Use of buprenorphine in pregnancy: patient management and effects 
on the neonate’, Drug and Alcohol Dependence 70, pp. 87–101.
Jones, H. E. (2004), ‘Practical considerations for the clinical 
use of buprenorphine’, Science and Practice Perspectives 2, No 2, 
pp. 4–20.
Kastelic, A. and Scott, R. (1998), ‘Buprenorphine: current perspectives’,
European Addiction Research, No 4.
Kosten, T. R., Schottenfeld, R., Ziedonis, D. and Falcioni, J. (1993),
‘Buprenorphine versus methadone maintenance for opioid dependence’,
Journal of Nervous and Mental Disease 181, pp. 358–64.
Selected issue 3: Buprenorphine — treatment, misuse and prescription practices
45
Ling, W., Wesson, D. R., Charuvastra, C. and Klett, C. J. (1996), 
‘A controlled trial comparing buprenorphine and methadone maintenance
in opioid dependence’, Archives of General Psychiatry 53, pp. 401–7.
Lintzeris, N., Clark, N., Muhkleisen, P. and Ritter, A. (2001), 
National clinical guidelines and procedures for the use of buprenorphine 
in the treatment of heroin dependence, Vorrath, E. (ed.), Commonwealth 
of Australia, Canberra, Australia.
Mello, N. K. and Mendelson, J. H. (1980), ‘Buprenorphine suppresses
heroin: use by heroin addicts’, Science 27, pp. 657–9.
Ministry of Health (1926), Departmental Committee on Morphine 
and Diamorphine Addiction, Ministry of Health, London.
Nordic studies on alcohol and drugs (2004), vol. 21, English supplement.
Observatoire Français des Drogues et des Toxicomanies (OFDT) (2004),
‘Les traitements de substitution en France: resultants récents 2004’,
Tendences, 37.
Pirnay, S., Borron, S. W., Giudicelli, C. P., et al. (2004), ‘A critical review
of the causes of death among post-mortem toxicological investigations:
analysis of 34 buprenorphine-associated and 35 methadone-associated
deaths’, Addiction 99, pp. 978–88.
Reitox national reports (2004) (http://www.emcdda.eu.int/?nnodeid=435).
Ridge, G., Lintzeris, N., Gossop, M., et al. (2004), The seven boroughs
buprenorphine study. Towards rational prescribing of buprenorphine 
and other opiate pharamcotherapies across the South London 
and Maudsley (SLAM) Trust, National Addiction Centres, London.
Schottenfeld, R. S, Pakes, J. R, Oliveto, A., et al. (1997), ‘Buprenorphine 
vs methadone maintenance treatment for concurrent opioid dependence
and cocaine abuse’, Archives of General Psychiatry 54, pp. 713–20.
Strain, E. C., Stitzer, M. L., Liebson, I. A. and Bigelow, G. E. (1994),
‘Comparison of buprenorphine and methadone in the treatment of opioid
dependence’, American Journal of Psychiatry 151, pp. 1025–30.
Vidal-Trecan, G., Varescon, I., Nabet, N. and Boissonnas, A. (2003),
‘Intravenous use of prescribed sublingual buprenorphine tablets by drug
users receiving maintenance therapy in France’, Drug and Alcohol
Dependence 69, pp. 175–81.
European Monitoring Centre for Drugs and Drug Addiction
Annual report 2005: selected issues
Luxembourg: Office for Official Publications of the European Communities
2005 — 45 pp. — 21 x 29.7 cm
ISBN 92-9168-246-2
SALES AND SUBSCRIPTIONS 
Publications for sale produced by the Office for Official Publications of the European 
Communities are available from our sales agents throughout the world. 
You can find the list of sales agents on the Publications Office website 
(http://publications.eu.int) or you can apply for it by fax (352) 29 29-42758. 
Contact the sales agent of your choice and place your order. 
ISBN 92-9168-246-2
,!7IJ2J1-gicegb!
T
D
-
A
F
-
0
5
-
0
0
1
-
E
N
-
C
About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
is one of the European Union’s decentralised agencies. Established in 1993
and based in Lisbon, it is the central source of comprehensive information
on drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates objective, reliable and
comparable information on drugs and drug addiction. In doing so, it
provides its audiences with an evidence-based picture of the drug
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide
range of audiences including policy-makers and their advisors;
professionals and researchers working in the drugs field; and, more
broadly, the media and general public.
The annual report presents the EMCDDA’s yearly overview of the drug
phenomenon in the EU and is an essential reference book for those seeking
the latest findings on drugs in Europe.
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